P246: Challenges in establishing best practices for gene therapy informed consent for hemophilia A/B
Year: 2024
Type: conference-abstract
Abstract: FDA approved gene therapy treatment for adults with hemophilia B became available in November 2022 and June 2023 for hemophilia A, and additional competing gene therapy clinical trials are underway. Unlike other genetic disorders for which gene therapy is available, hemophilia A and B each have effective alternative treatment options that have more long-term safety and efficacy data. Additionally, there may eventually be competing options for gene therapies that could further improve clinical outcomes.
Source: Genetics in Medicine Open
Authors: Kristy Lee, Callie Berkowitz, Kristi Jackson, Brenda Nielsen, Patrick Ellsworth, Alice Ma, Nigel Key
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,200
OpenAlex ID: W4392589134
